Individuals who developed type 1 diabetes (T1D) in adulthood faced a higher risk for all-cause mortality and major adverse cardiovascular events (MACEs) than individuals from the general population ...

Outside of genetics, which has a well-documented link to the risk of type 1 diabetes (T1D), investigators detail available research spanning a variety of factors, including viral infections, pesticide ...

VIENNA — Drugs that are already approved for other purposes are showing promise in slowing disease progression in people with new-onset type 1 diabetes (T1D), according to the results of three ...

Type 1 diabetes (T1D) impacts around 9.5 million people (1.9 million people under 20) across the world and is a leading chronic health condition impacting those under the age of 18.1 As the condition ...

The Type 1 Diabetes (T1D) Index measures global T1D prevalence and provides other statistics and estimates related to the autoimmune condition. The JDRF, formerly known as the Juvenile Diabetes ...

New research (the Ver-A-T1D trial) presented at the Annual Meeting of the European Association for the Study of Diabetes (EASD) (Vienna, 15–19 September) shows that slow-release (SR) verapamil (360mg ...

Breakthrough T1D, the leading global type 1 diabetes (T1D) research and advocacy organization and SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a ...

SAB-142 shows favorable safety and pharmacodynamic activity in Phase 1 trial, advancing to Phase 2b for type 1 diabetes. SAB BIO announced positive results from its Phase 1 trial of SAB-142, a novel ...

Scientists uncover how exposure to a mother’s type 1 diabetes during pregnancy may epigenetically “reprogram” her child’s immune system, offering new clues to lifelong protection against the disease.